Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Christiane Bickert"'
Autor:
Christiane Bickert, Kathrin Kahnert, Diego Kauffmann-Guerrero, Jeremias Götschke, Zulfiya Syunyaeva, Jürgen Behr, Amanda Tufman
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Osimertinib is a third-generation tyrosine kinase inhibitor that became the preferred first-line treatment option for metastatic non-small cell lung cancer with sensitizing epidermal growth factor receptor mutations. Drug-induced pneumonitis is known
Externí odkaz:
https://doaj.org/article/c6f2a3bde74748069d604deaa8a7e3c3
Autor:
Rudolf A. Jörres, Claus Vogelmeier, Joachim H. Ficker, Franziska C. Trudzinski, Peter Alter, Christiane Bickert, Tobias Welte, Kathrin Kahnert, Henrik Watz, Pontus Mertsch, Robert Bals, Jürgen Behr, Tanja Lucke
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Kathrin Kahnert,1 Rudolf A Jörres,2 Tanja Lucke,2 Franziska C Trudzinski,3 Pontus Mertsch,1 Christiane Bickert,1 Joachim H Ficker,4 Jürgen Behr,1 Robert Bals,5 Henrik Watz,6 Tobias Welte,7 Claus F Vogelmeier,8 Peter Alter8 On behalf of COSYCONE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0132905d70ee473812e2dfd60fc0c47
https://doi.org/10.2147/copd.s335029
https://doi.org/10.2147/copd.s335029
Autor:
Franziska C. Trudzinski, Felix J.F. Herth, Jürgen Behr, Rudolf A. Jörres, Katrin Milger, Christiane Bickert, Michael Irlbeck, Nikolaus Kneidinger, Sebastian Michel, Dieter Munker, Kathrin Kahnert, Roland Tomasi, Christian Schneider
Publikováno v:
Transplantation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8880d99a3e9706515928363e4ab7453
https://doi.org/10.1183/13993003.congress-2021.oa2915
https://doi.org/10.1183/13993003.congress-2021.oa2915
Autor:
Jeremias Götschke, Christiane Bickert, Kathrin Kahnert, Zulfiya Syunyaeva, Jürgen Behr, Amanda Tufman, Diego Kauffmann-Guerrero
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Osimertinib is a third generation Tyrosine Kinase Inhibitor (TKI) that has become an effective first-line treatment option for metastatic non-small cell lung cancer with sensitizing epidermal growth factor receptor (EGFR) mutations. It demonstrated e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f0608a38271b87248ccd465aabc5884
http://europepmc.org/articles/PMC8202262
http://europepmc.org/articles/PMC8202262
Autor:
Steffen U. Eisenhardt, Alba Fricke, Georg W. Herget, Jutta Scholber, Holger Bannasch, Peter Bronsert, Christiane Bickert, Anja E. Eisenhardt, Marie Follo, Rainer Claus, David Braig, G. Bjoern Stark, Juergen Heinz, Moritz Braig, Caroline Becherer
Soft tissue sarcomas (STS) are rare tumors of mesenchymal origin. About 50% of patients with STS experience relapse and more than 30% will die within 10 years after diagnosis. In this study we investigated circulating free DNA (cfDNA) and tumor-speci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::360c2c3004606f2a10859039dc490ced
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/58460
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/58460
